US Patent Issued to SHANGHAI EPIPROBE BIOTECHNOLOGY on Sept. 29 for "Tumor marker stamp-EP3 based on methylation modification" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,747,477, issued on Sept. 29, was assigned to SHANGHAI EPIPROBE BIOTECHNOLOGY Co. LTD. (Shanghai).

"Tumor marker stamp-EP3 based on methylation modification" was invented by Zhenyan Li (Shanghai) and Shihua Dong (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a methylation tumor marker STAMP-EP3 and use thereof, and belongs to the field of disease diagnosis markers. The present invention provides use of the methylation tumor marker STAMP-EP3 in the preparation of a tumor diagnosis reagent."

The patent was filed on Dec. 30, 2019, under Application No. 17/309,898.

*For further information, including images, charts...